Micafungin sodium, JP/USP/Ph. Eur. grade, is supplied as a pharmaceutical-grade active pharmaceutical ingredient for the manufacture of tablets, capsules, granules, and injectable preparations. The substance is a semisynthetic echinocandin lipopeptide obtained from a fermentation product of Coleophoma empetri and is presented as the monosodium salt with CAS 208538-73-2 and molecular weight 1292.26 g/mol. The molecule inhibits fungal β-1,3-D-glucan synthase, an enzyme absent from mammalian cells; the resulting loss of cell-wall β-D-glucan is concentration-independent and leads to osmotic fragility and lysis of susceptible Candida and Aspergillus species. The API is a white to off-white hygroscopic powder; oral solid-dose grade and injectable grade are distinguished by particle size control, residual moisture, bioburden, and endotoxin burden. The designation “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” is a supply specification rather than a pharmacopoeial name; it indicates release under Good Manufacturing Practice with documentation supporting either non-sterile solid oral processing or sterile injectable processing. The oral tablet, capsule, and granule route is not an approved systemic delivery pathway in major markets because micafungin sodium exhibits negligible oral bioavailability; published data for specific oral micafungin configurations is limited. Consequently, oral-grade API is used for investigational formulations, local-action or non-systemic research dosage forms, and bioavailability screening, whereas the injectable grade is processed aseptically or lyophilized for intravenous antifungal therapy. The product model is manufacturer-specific; it is assigned as micafungin sodium, pharma grade API, with a fine-particle specification for dry granulation, tableting, and encapsulation, and a low-endotoxin, low-moisture specification for sterile injection.

Specification limits and pharmacopoeial alignment for micafungin sodium

Release specifications are established against the current pharmacopoeial monograph and the general chapters for HPLC, residual solvents, water content, elemental impurities, and microbiological quality. Typical release criteria are summarized below for the powder used in oral solid and injectable manufacturing; compendial monographs may not specify every attribute for the API alone, and the certificate of analysis is the controlling document for a given lot. HPLC assay and related-substance methods use octadecylsilyl stationary phases with gradient elution and UV detection; system suitability is verified per USP <621> and Ph. Eur. 2.2.29. Identification by infrared absorption spectrophotometry uses attenuated total reflectance, and retention time identification uses a reference standard co-injection; the retention time must fall within ±0.1 min of the standard.

Residual solvent analysis is performed by headspace gas chromatography with flame ionization detection according to USP <467> and Ph. Eur. 5.4; the manufacturing route controls ethanol, acetone, and ethyl acetate to ICH Q3C Option 2 levels, with lot-specific values reported on the certificate of analysis. The powder is stored in an airtight container, protected from light, at 2–8 °C or as specified by the manufacturer. Repeated warming to ambient temperature under uncontrolled humidity is discouraged because the hygroscopic sodium salt can absorb sufficient water to initiate particle bridging and agglomeration. If Karl Fischer water exceeds the release limit, vacuum drying at 40 °C for 24 h may be used only after validation, because the echinocandin nucleus is subject to thermal and hydrolytic degradation.

For oral solid grade, microbiological examination follows USP <61>/<62> and Ph. Eur. 2.6.12/2.6.13; acceptance criteria are assigned from the finished dosage form and are not universal for all tableting or encapsulation operations. For injectable grade, bacterial endotoxin and sterility are not inherently achieved by the API powder alone; they are verified after dissolution, filtration through a 0.22 µm sterilizing filter, and aseptic filling or lyophilization according to Ph. Eur. 2.6.14 and USP <85>. Bulk packaging commonly uses double low-density polyethylene liners inside an aluminum foil laminate pouch with desiccant; the outer drum is labeled with batch number, retest date, storage temperature, and the grade statement for oral solid or injectable use.

Why does micafungin sodium require route-specific grade controls for oral and injectable manufacture?

Two physical grades are required because powder handling, moisture sensitivity, and bioburden control differ between dry-granulation tableting and aseptic lyophilization. The sodium salt is hygroscopic; a wet granulation step can introduce phase heterogeneity, hydrate formation, and loss of assay. Dry granulation by roller compaction or slugging is therefore preferred for oral tablet and capsule formulations. Production-scale failures associated with hygroscopic sodium salts include punch sticking, capping, and increasing weight variability after hopper residence times beyond 4 h in uncontrolled humidity. Material transfer is performed under dry-air or nitrogen overlay with a target room condition of 25 ± 5 °C and ≤30% relative humidity. The manufacturing line should be equipped with dust extraction or an isolator because the API is a particulate; operator exposure limits are assigned from the safety data sheet and local occupational exposure guidance.

Particle size distribution for oral solid dosage forms is controlled by laser diffraction according to USP <429> and Ph. Eur. 2.9.31. A manufacturer may set d₉₀ ≤ 150 µm with ≤20% fines below 45 µm to maintain flow and die-fill consistency; these values are not universal and must be correlated with tablet hardness, capsule fill weight, and granule flow. Blend uniformity and content uniformity follow USP <905> and Ph. Eur. 2.9.40. Direct compression is possible only if flow and compressibility are controlled; otherwise dry granulation is used to densify the API with microcrystalline cellulose, lactose, crospovidone, or other pharmacopoeial excipients. The API is typically present at low mass per unit dose; geometric dilution and co-milling are therefore required to achieve consistent distribution. Segregation in hopper feed frames is minimized by using polished stainless steel surfaces and reduced drop heights.

Injectable manufacture requires a different set of controls. Micafungin sodium is dissolved in Water for Injection, pH-adjusted with citric acid/sodium hydroxide, and filtered through a 0.22 µm sterilizing filter before aseptic filling or lyophilization. The final solution is typically filled into Type I borosilicate glass vials; terminal steam sterilization at 121 °C is not recommended because the glycosidic and peptide bonds of the echinocandin may degrade. After lyophilization, residual moisture is limited to ≤2.5% to suppress hydrolytic degradation. Particulate matter is controlled by USP <788> and Ph. Eur. 2.9.19. The sodium counterion contributes to tonicity; formulation calculations must include the sodium content of the salt to avoid hypertonic reconstituted solutions at high doses.

Operational boundaries are explicit. Micafungin sodium should be protected from light and excessive humidity. Aqueous solutions should not be autoclaved; strong oxidizing agents, reducing agents, and prolonged exposure to pH below 3 or above 9 should be avoided because the lipopeptide backbone is susceptible to acid/base hydrolysis. The oral-grade API is not interchangeable with sterile injectable grade because oral grade may not meet bacterial endotoxin limits or sterile processing expectations. Conversely, injectable grade may contain no preservatives and is not intended for direct oral administration without further formulation safety assessment.

When Micafungin Sodium Replaces Caspofungin Acetate or Anidulafungin in Parenteral Antifungal Formulation

The substitution decision is not an active-equivalence calculation; each echinocandin differs in molecular weight, salt form, solubility, degradation route, and diluent compatibility. Micafungin sodium is the monosodium salt with molecular weight 1292.26 g/mol; caspofungin acetate is a diacetate salt with molecular weight 1213.42 g/mol; anidulafungin is a free-base lipopeptide with molecular weight 1140.24 g/mol. These differences affect the amount of free active base delivered per milligram of salt and the pH adjustment required before intravenous administration.

Micafungin sodium inhibits β-1,3-D-glucan synthase selectively; the same mechanism is shared by caspofungin and anidulafungin, but the side-chain structure and metabolism differ. Micafungin sodium is metabolized by arylsulfatase and catechol-O-methyltransferase, with subsequent fecal excretion; this pathway is not CYP3A4-dependent, reducing azole-like drug-interaction burden. Caspofungin acetate is metabolized by hepatic hydrolysis and N-acetylation; anidulafungin is not metabolized by the liver and undergoes slow chemical degradation to an inactive peptide. These differences affect the clinical labeling in severe hepatic impairment and the in vitro susceptibility breakpoints applied in candidiasis surveillance according to CLSI M27 and EUCAST E.DEF 9.1.

Micafungin sodium is generally described as compatible with 0.9% sodium chloride and 5% dextrose injection; caspofungin acetate is not diluted in dextrose-containing solutions because of physical or chemical stability limitations. Anidulafungin is supplied as a sterile concentrate containing alcohol and is diluted according to the approved label. The formulary substitution of one echinocandin for another requires consideration of the reconstitution volume, the final concentration, the infusion time, and the sodium or acetate load; these variables are not harmonized among the three APIs.

Oral tablet and capsule grades of micafungin sodium are not bioequivalent to oral azole antifungal agents such as fluconazole or itraconazole because the systemic absorption of micafungin sodium from the gastrointestinal tract is negligible. Any comparison to oral azole products must account for the absence of published bioequivalence standards for oral micafungin sodium; there is no recognized USP/Ph. Eur./JP oral tablet monograph for micafungin sodium. In contrast, parenteral micafungin sodium is differentiated from azoles and polyenes by its echinocandin mechanism, which does not bind to ergosterol and does not inhibit CYP51; this narrows the off-target sterol-binding toxicities but also restricts the spectrum to susceptible Candida and Aspergillus species.

Stability profiles differ. Micafungin sodium requires protection from light and humidity; caspofungin acetate requires refrigerated storage before reconstitution and has a limited room-temperature window after dilution; anidulafungin is supplied as a refrigerated concentrate and must be diluted with care to avoid precipitation. The exact storage times and temperatures are product-specific and must follow the approved finished-product labeling; no single set of conditions applies to all echinocandin formulations. For manufacturing-scale planning, the API vendor’s certificate of analysis and the finished product’s stability data under ICH Q1A conditions are the controlling references.